GH secretagogue side effects
Side effects across Ipamorelin, CJC-1295, MK-677, Sermorelin, and Tesamorelin — water retention, tingling, insulin, and the carpal tunnel question.
Updated May 7, 2026 · 5 min read
GH secretagogue side effects are mostly mild but specific to the class — water retention, mild tingling, appetite shifts, and insulin sensitivity questions are all on the table. The intensity varies by peptide, with Ipamorelin and Sermorelin at the gentle end and CJC-1295 with DAC and MK-677 at the more aggressive end.
The category-wide effects
| Effect | Frequency | Severity | What to do |
|---|---|---|---|
| Numbness or tingling in hands or feet | Common with DAC, occasional with no-DAC | Mild | Reduce dose; usually adapts |
| Increased appetite | Universal with MK-677, mild with Ipamorelin | Variable | Plan around it; reduce dose |
| Water retention | Common, dose-dependent | Mild | Reduce sodium; reduce dose |
| Insulin sensitivity changes | Variable | Moderate | Track fasting glucose; stop if pre-diabetic |
| Carpal tunnel symptoms | Occasional, dose-dependent | Moderate | Reduce dose; stop if persistent |
| Vivid dreams | Common | Benign | Often a positive signal |
| Joint aches | Occasional | Mild | Usually transient; resolves with dose reduction |
| Mild fatigue | Common in first 2 weeks | Mild | Adapts |
By peptide — comparative profile
Ipamorelin (gentlest)
| Effect | Profile |
|---|---|
| Cortisol elevation | Almost none |
| Prolactin elevation | Almost none |
| Appetite | Minor |
| Water retention | Minor |
| Insulin sensitivity | Minor |
Ipamorelin's selective profile is its whole pitch. It triggers GH release without significantly raising cortisol or prolactin (unlike older GHRPs like GHRP-2 and GHRP-6). Most users tolerate it well.
CJC-1295 (no DAC)
Similar profile to Ipamorelin — short half-life means less sustained elevation, less side-effect intensity. Most users running the Ipa+CJC no-DAC stack report a clean profile.
CJC-1295 with DAC
| Effect | Profile |
|---|---|
| Numbness / tingling | More common |
| Water retention | More pronounced |
| Insulin sensitivity drift | More noticeable on long runs |
| Joint aches | Occasionally significant |
The DAC modification's sustained-elevation profile is what produces the more aggressive side-effect picture. Worth taking seriously.
MK-677 (oral)
| Effect | Profile |
|---|---|
| Appetite increase | Pronounced |
| Water retention | Common, can be significant |
| Lethargy first 2 weeks | Common |
| Insulin sensitivity drift | Reported on long runs (3+ months) |
| Cortisol / prolactin | Mild elevation possible |
MK-677's oral convenience comes with the most pronounced side-effect profile in the category. The insulin-sensitivity question is the most serious open issue — pre-diabetics should not run MK-677.
Sermorelin
The gentlest GHRH analogue. Side-effect profile similar to Ipamorelin — most users report little beyond vivid dreams and occasional injection-site reactions.
Tesamorelin
Stronger than Sermorelin, with the most clinical data (FDA-approved for HIV-LD). Side effects similar to other GHRH analogues:
- Mild numbness / tingling
- Injection-site reactions
- Joint pain (occasional, dose-dependent)
- Glucose elevation (well-documented in trials)
The carpal tunnel question
Carpal tunnel symptoms — tingling, numbness, weakness in the hands — are a documented side effect of supraphysiologic GH elevation. Secretagogues can produce this, but at therapeutic doses it's uncommon.
Risk factors:
- High doses (above standard ranges)
- Long-acting formulations (CJC-1295 with DAC especially)
- Pre-existing repetitive-stress wrist issues
- Stacking multiple GH-axis activators
If symptoms appear:
- Mild, transient: reduce dose 50%; usually resolves
- Persistent past 2 weeks: stop the GH secretagogue; symptoms typically resolve within a few weeks
- Numbness affecting grip strength or fine motor control: stop immediately; consult a clinician
The insulin / blood sugar question
GH and IGF-1 elevation can shift insulin sensitivity. The pattern varies:
| Peptide | Insulin impact |
|---|---|
| Ipamorelin | Minimal |
| CJC-1295 (no DAC) | Mild |
| CJC-1295 (with DAC) | Moderate, especially long-term |
| MK-677 | Moderate-significant on long runs |
| Sermorelin | Mild |
| Tesamorelin | Moderate (well-documented) |
Tracking strategy if you're running any of these:
- Baseline labs: fasting glucose, HbA1c, fasting insulin, HOMA-IR if your clinician will run it
- Re-check at week 8 and end of cycle
- Stop signal: fasting glucose drifts above 100 mg/dL, A1C rises past 5.6, or fasting insulin elevation
The cancer / IGF-1 question
GH secretagogues raise IGF-1. IGF-1 is implicated in cellular proliferation pathways. The mechanism case for caution is real even if a clean human signal hasn't been established at therapeutic doses.
- Active or recent cancer: absolute contraindication
- Strong family history of hormone-sensitive cancer (breast, prostate, colorectal): discuss with a clinician
- Standard population: the risk is theoretical at therapeutic doses; routine cancer screening per age guidelines is appropriate
When to stop
| Symptom | Action |
|---|---|
| Persistent numbness affecting grip | Stop immediately |
| Fasting glucose over 100 mg/dL | Stop and re-evaluate |
| Significant water retention not responding to dose reduction | Stop |
| New lump, change in mole, unusual bleeding | Stop and consult clinician |
| Severe persistent headache | Stop and consult clinician |
| Visual changes | Stop and consult clinician |
Drug interactions
- Insulin / oral hypoglycemics: secretagogues can shift insulin needs — coordinate with prescribing clinician
- Corticosteroids: can blunt GH response and amplify side effects
- Thyroid medications: GH/T4 conversion shifts can occur — monitor labs
Pregnancy and lactation
Not studied. Don't.